Medifast (MED) director Scott Schlackman adds 5,000 shares in open-market buys

Rhea-AI Filing Summary

Medifast Inc. director Scott Schlackman reported open-market purchases of company stock. He bought 2,500 shares of Common Stock on May 8, 2026 at $12.65 per share and another 2,500 shares on May 11, 2026 at $12.53 per share. These transactions total 5,000 shares and were classified as open-market purchases. Following the later transaction, Schlackman directly owns 30,548.707 shares of Medifast Common Stock.

Insider Trade Summary

Net Buyer: 5,000 shares ($62,950)

Net Buy 2 txns

Insider SCHLACKMAN SCOTT

Role null

Bought 5,000 shs ($63K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,500	$12.53	$31K
Purchase	Common Stock	2,500	$12.65	$32K

Holdings After Transaction: Common Stock — 30,548.707 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased May 8, 2026: 2,500 shares Shares purchased May 11, 2026: 2,500 shares Total shares bought: 5,000 shares +3 more

6 metrics

Shares purchased May 8, 2026 2,500 shares Open-market purchase at $12.65 per share

Shares purchased May 11, 2026 2,500 shares Open-market purchase at $12.53 per share

Total shares bought 5,000 shares Net buy across two transactions

Holding after latest trade 30,548.707 shares Direct ownership following May 11, 2026 purchase

Purchase price May 8, 2026 $12.65 per share Common Stock open-market purchase

Purchase price May 11, 2026 $12.53 per share Common Stock open-market purchase

Key Terms

Common Stock, open-market purchase, transaction code P, direct ownership, +1 more

5 terms

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

transaction code P financial

"transaction_code_description: "Purchase in open market or private transaction""

direct ownership financial

"ownership_type: "direct" and ownership_code: "D""

non-derivative financial

"transaction_type: "non-derivative""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCHLACKMAN SCOTT

(Last) (First) (Middle)

C/O MEDIFAST, INC.

1501 S. CLINTON STREET

(Street)

BALTIMORE MARYLAND 21224

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MEDIFAST INC [ MED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/08/2026		P		2,500	A	$12.65	28,048.707	D
Common Stock	05/11/2026		P		2,500	A	$12.53	30,548.707	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Jason L. Groves, attorney-in-fact	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Medifast (MED) disclose for Scott Schlackman?

Medifast disclosed that director Scott Schlackman made two open-market purchases of Common Stock, each for 2,500 shares. The trades occurred on May 8 and May 11, 2026, and were reported as non-derivative transactions under transaction code P.

How many Medifast (MED) shares did the director buy and at what prices?

Scott Schlackman bought a total of 5,000 Medifast Common Stock shares. He purchased 2,500 shares at $12.65 per share on May 8, 2026, and another 2,500 shares at $12.53 per share on May 11, 2026, in open-market transactions.

What is Scott Schlackman’s Medifast (MED) share ownership after these trades?

After the May 11, 2026 purchase, Scott Schlackman directly owns 30,548.707 Medifast Common Stock shares. This total reflects the cumulative effect of the reported 5,000-share open-market purchases and is listed as his direct beneficial ownership following the latest transaction.

Were the recent Medifast (MED) insider transactions buys or sells?

The recent Medifast insider transactions by director Scott Schlackman were buys. Both entries carry transaction code P and are described as open-market purchases of Common Stock, totaling 5,000 shares, with no reported sales or derivative transactions in this filing.

Does the Medifast (MED) Form 4 show any derivative securities activity?

The Form 4 for Medifast indicates no derivative securities activity for Scott Schlackman. All reported transactions involve non-derivative Common Stock, and the derivative summary section shows zero derivative transactions and zero remaining derivative positions in this specific filing.